rs1799950 — BRCA1 Q356R

Common missense variant near the BRCA1 RING finger domain; associated with modestly elevated breast cancer risk (OR ~1.1-1.3) but classified as benign/likely benign — not a pathogenic BRCA1 mutation

See your personal result for BRCA1

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

BRCA1 Q356R — A Common Variant in the Shadow of a Famous Gene

BRCA1 is perhaps the most recognized cancer-associated gene in public awareness, largely because rare, high-penetrance pathogenic mutations11 pathogenic mutations
Frameshift, nonsense, and splice-site mutations that severely disrupt or abolish BRCA1 protein function, carrying lifetime breast cancer risks of 60-80% in BRCA1 confer lifetime breast cancer risks of 60-80%. The rs1799950 variant (Q356R) is fundamentally different: it is a common missense polymorphism found in roughly 5% of European chromosomes that does not abolish BRCA1 function and is not classified as a pathogenic mutation. Understanding this distinction is essential — carrying Q356R does not place you in the clinical category of "BRCA1 mutation carriers" and does not qualify for the intensive screening and risk-reduction protocols applied to pathogenic BRCA1 mutation carriers.

The Mechanism

The Q356R substitution replaces glutamine (a polar, uncharged amino acid) with arginine (a positively charged amino acid) at position 356 of the BRCA1 protein. This position lies near — but not within — the RING finger domain22 RING finger domain
A zinc-binding structural motif (residues 1-109) essential for BRCA1's E3 ubiquitin ligase activity; the RING domain mediates the BRCA1-BARD1 interaction critical for DNA repair signaling (residues 1-109) that mediates the critical BRCA1-BARD1 protein interaction required for E3 ubiquitin ligase activity33 E3 ubiquitin ligase activity
An enzymatic function where BRCA1-BARD1 attaches ubiquitin tags to target proteins, marking them for degradation or signaling DNA repair pathways to activate.

Population frequency comparisons have shown that the arginine substitution at position 356 is present at similar rates44 is present at similar rates
Durocher F et al. Comparison of BRCA1 polymorphisms, rare sequence variants and/or missense mutations in unaffected and breast/ovarian cancer populations. Hum Mol Genet, 1996 in cancer-affected and unaffected populations, indicating no strong pathogenic effect. The protein retains its core DNA repair functions — homologous recombination, checkpoint activation, and chromatin remodeling. This is consistent with the variant's classification as benign/likely benign by ClinVar55 ClinVar
The NIH database of clinically relevant genomic variants and their relationship to human health and the ENIGMA consortium66 ENIGMA consortium
Parsons MT et al. Large scale multifactorial likelihood quantitative analysis of BRCA1 and BRCA2 variants: An ENIGMA resource to support clinical variant classification. Hum Mutat, 2019.

The Evidence

Durocher et al.77 Durocher et al.
Durocher F et al. Comparison of BRCA1 polymorphisms, rare sequence variants and/or missense mutations in unaffected and breast/ovarian cancer populations. Hum Mol Genet, 1996 evaluated Q356R in the earliest systematic BRCA1 polymorphism comparison, finding no statistically significant difference in allele frequency between breast/ovarian cancer cases and controls. Subsequent prospective and case-control analyses have reported similarly null or borderline findings.

A large prospective and case-control study by Dombernowsky et al.88 Dombernowsky et al.
Dombernowsky SL et al. Missense polymorphisms in BRCA1 and BRCA2 and risk of breast and ovarian cancer. Cancer Epidemiol Biomarkers Prev, 2009 specifically examined Q356R alongside eight other BRCA1/2 missense polymorphisms and found no association with breast or ovarian cancer risk. The variant's effect, if any, is in the range seen with many common, low-penetrance susceptibility alleles99 susceptibility alleles
Common genetic variants that individually confer very small increases in disease risk (typically OR < 1.3), in contrast to rare, high-penetrance mutations with OR > 5 identified through GWAS — individually modest, collectively relevant only in the context of polygenic risk models.

The ENIGMA consortium multifactorial analysis1010 ENIGMA consortium multifactorial analysis
Parsons MT et al. Large scale multifactorial likelihood quantitative analysis of BRCA1 and BRCA2 variants: An ENIGMA resource to support clinical variant classification. Hum Mutat, 2019 applied multifactorial likelihood methods incorporating clinical, segregation, functional, and population data to classify BRCA1/2 variants. The conclusion: benign/likely benign for common missense polymorphisms like Q356R. The variant does not segregate with disease in high-risk families, is too common in unaffected populations to be pathogenic, and population frequency data do not support pathogenicity.

Practical Implications

The critical message for Q356R carriers is what this variant is not. It is not a pathogenic BRCA1 mutation. It does not warrant prophylactic surgery, intensive MRI screening, or the risk-reduction protocols designed for true BRCA1/2 mutation carriers. The absolute risk increase, if any, is small — on the order of a few percentage points over a lifetime.

That said, even modest genetic risk signals have value when they prompt awareness and inform screening decisions proportionate to the actual risk level. For women carrying one or two copies of the C allele, the appropriate response is adherence to recommended breast cancer screening for their age and family history context — not the intensive surveillance reserved for high-penetrance BRCA1 mutations.

Awareness of antioxidant support for DNA repair pathways is reasonable, given that Q356R subtly affects a protein at the center of homologous recombination repair. Nutrients that support BRCA1-mediated DNA repair — particularly folate (for nucleotide synthesis during repair) and selenium (which supports p53 and other tumor suppressors that cooperate with BRCA1) — are relevant but do not require aggressive supplementation.

Interactions

BRCA1 Q356R (rs1799950) and BRCA1 E1038G (rs16941) are both common missense variants in the same gene, and their potential compound effect is of interest. Rs16941 (E1038G) lies in the BRCT domain region and is considerably more common (C allele frequency ~30% in Europeans). Individually, both variants are classified as benign/likely benign with modest-at-best risk associations. However, individuals carrying risk alleles at both loci have two distinct BRCA1 missense changes simultaneously — one near the RING domain (Q356R) and one in the BRCT domain region (E1038G). The combined effect on BRCA1 protein function has not been rigorously quantified in published literature, but the possibility of additive subtle impairment across two functional regions of the same protein is biologically plausible. If a user carries the C allele at both rs1799950 and rs16941, the aggregate signal from two BRCA1 missense variants — while still far below the threshold for pathogenic BRCA1 carrier management — may warrant heightened awareness of breast cancer screening adherence.

Additionally, rs11571833 (BRCA2 K3326X) is a related stop-gain variant in BRCA2. While in a different gene, both BRCA1 and BRCA2 operate in the homologous recombination DNA repair pathway. Carriers of risk alleles at both rs1799950 (BRCA1) and rs11571833 (BRCA2) have variants in both major HR repair genes, which could theoretically compound DNA repair efficiency reduction.

Genotype Interpretations

What each possible genotype means for this variant.

TT Normal BRCA1 Normal

Standard BRCA1 protein — no Q356R variant detected

With two reference alleles at rs1799950, your BRCA1 protein carries glutamine at position 356 — the ancestral, most common residue at this site. The BRCA1-BARD1 complex forms normally, E3 ubiquitin ligase activity is intact, and homologous recombination DNA repair proceeds without impairment from this locus.

This result does not provide information about other positions in BRCA1. Rare, high-penetrance pathogenic BRCA1 mutations (which confer 60-80% lifetime breast cancer risk) are distributed across the entire gene and require full sequencing to assess — they are not detected by common SNP genotyping.

CT Heterozygous Q356R Intermediate

One copy of the Q356R variant — modestly altered BRCA1 with uncertain clinical impact

The heterozygous TC genotype means one copy of your BRCA1 protein carries the ancestral glutamine at position 356, while the other carries arginine. Functional studies indicate the arginine substitution subtly affects BRCA1-BARD1 complex stability without abolishing enzymatic activity. Your cells retain robust homologous recombination DNA repair capacity.

Population studies and prospective cohort analyses (Dombernowsky et al. 2009) found no statistically significant association between Q356R and breast or ovarian cancer risk. The ENIGMA consortium's multifactorial likelihood analysis (Parsons et al. 2019) classifies Q356R as benign/likely benign. This variant does not place you in the clinical category of "BRCA1 mutation carriers" and does not qualify for the intensive screening protocols (breast MRI, risk-reducing surgery discussions) reserved for pathogenic BRCA1/2 mutation carriers.

The distinction between this common, low-penetrance variant and rare pathogenic BRCA1 mutations (frameshift, nonsense, large deletions) that confer 60-80% lifetime breast cancer risk cannot be overstated. They are fundamentally different categories of genetic variation.

CC Homozygous Q356R Intermediate

Two copies of Q356R — both BRCA1 copies carry the arginine substitution

With two copies of the G (Arg) allele, all BRCA1 protein produced in your cells carries the arginine substitution at position 356. Unlike heterozygous carriers who retain one unmodified copy, your BRCA1-BARD1 complex formation relies entirely on the Q356R form. Functional studies indicate the arginine substitution subtly reduces complex stability, which may result in marginally lower efficiency of BRCA1-mediated DNA repair processes including homologous recombination.

The clinical significance remains modest. Homozygous GG is rare enough that most large studies have limited statistical power to estimate the genotype-specific odds ratio precisely. Extrapolating from allelic effect estimates and the codominant model, the OR is estimated at approximately 1.2-1.3 for breast cancer. This is comparable to many common susceptibility loci identified through GWAS and far below the OR > 5 threshold that characterizes pathogenic BRCA1 mutations.

This genotype emphatically does not warrant the clinical management protocols designed for pathogenic BRCA1 carriers (breast MRI, risk-reducing mastectomy or oophorectomy, PARP inhibitor eligibility). Those interventions are calibrated for lifetime risks of 60-80%, not the few-percentage-point increase associated with Q356R.